Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Welsch

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Journal of Clinical Microbiology|July 30, 2010
Performance of the Abbott RealTime CT/NG for detection of Chlamydia trachomatis and Neisseria gonorrhoeaeC A Gaydos, C P Cartwright, P Colaninno, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 1999
Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiolsJ N Freskos, B V Mischke, G A DeCrescenzo, et al.
Molecular Cancer Therapeutics|September 24, 2017
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)Ursula A Germann, Brinley F Furey, William Markland, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS)Chris P Carron, John I Trujillo, Kirk L Olson, et al.
Cancer Discovery|June 16, 2018
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision MedicineAndrew J Aguirre, Jonathan A Nowak, Nicholas D Camarda, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Journal of Clinical Microbiology|July 30, 2010
Performance of the Abbott RealTime CT/NG for detection of Chlamydia trachomatis and Neisseria gonorrhoeaeC A Gaydos, C P Cartwright, P Colaninno, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 1999
Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiolsJ N Freskos, B V Mischke, G A DeCrescenzo, et al.
Molecular Cancer Therapeutics|September 24, 2017
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)Ursula A Germann, Brinley F Furey, William Markland, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS)Chris P Carron, John I Trujillo, Kirk L Olson, et al.
Cancer Discovery|June 16, 2018
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision MedicineAndrew J Aguirre, Jonathan A Nowak, Nicholas D Camarda, et al.
Pageof 5